Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Non-Current Liabilities (2016 - 2025)

Zevra Therapeutics' Total Non-Current Liabilities history spans 9 years, with the latest figure at $128.4 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 6.39% year-over-year to $128.4 million; the TTM value through Dec 2025 reached $128.4 million, up 6.39%, while the annual FY2025 figure was $128.4 million, 6.39% up from the prior year.
  • Total Non-Current Liabilities reached $128.4 million in Q4 2025 per ZVRA's latest filing, up from $119.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $128.4 million in Q4 2025 to a low of $4.2 million in Q1 2022.
  • Average Total Non-Current Liabilities over 5 years is $61.5 million, with a median of $43.4 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 92.62% in 2021, then skyrocketed 2003.11% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $5.8 million in 2021, then soared by 593.97% to $40.2 million in 2022, then soared by 156.26% to $103.0 million in 2023, then increased by 17.14% to $120.7 million in 2024, then increased by 6.39% to $128.4 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Total Non-Current Liabilities are $128.4 million (Q4 2025), $119.5 million (Q3 2025), and $121.6 million (Q2 2025).